Merck & Co.

Diversified pharma

MRK · NYSE · United States

Share price · MRK

$137.78+2.61 (+1.93%) 3M

close as of 2026-11-18 · 24h delayed · vol 9.7M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MRK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 Oct 2026-3.3%
  2. 25 Aug 2026+3.8%
  3. 19 Aug 2026+12.6%
  4. 1 Jul 2026-2.4%
  5. 15 Jun 2026-3.5%
  6. 22 May 2026+5.6%
  7. 1 May 2026+2.7%
  8. 21 Apr 2026-3.9%
  9. 3 Feb 2026+2.2%
  10. 8 Jan 2026+2.2%

Share of unusual movement by asset

For each asset, the share of MRK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Pembrolizumab
events and moves
92%
Pembrolizumab berahyaluronidase alfa (Keytruda Qlex)
events and moves
7shown from 8 days
Sotatercept (Winrevair)
events and moves
5shown from 8 days
ensifentrine (Ohtuvayre)
events and moves
3shown from 8 days
Intismeran Autogene
events and moves
3shown from 8 days
Sacituzumab Tirumotecan
events and moves
3shown from 8 days
Ifinatamab Deruxtecan
events and moves
2shown from 8 days
tulisokibart
events and moves
1shown from 8 days
efinopegdutide
events and moves
1shown from 8 days
Islatravir
events and moves
1shown from 8 days
Enlicitide (Lipfendra)
events and moves
1shown from 8 days
HRS-5346
events and moves
1shown from 8 days
Patritumab Deruxtecan
events and moves
1shown from 8 days
Doravirine/islatravir (Idvynso) (Idvynso)
events and moves
1shown from 8 days
Tucatinib
events and moves
1shown from 8 days
Islatravir/lenacapavir
events and moves
1shown from 8 days
Clesrovimab (Enflonsia)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—20%
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—62%

Assets

(54 total)
54Total Assets
19Approved
17Phase 3 / Filed
18Phase 1–2 / Early
54Diseases
Quick filter:
Showing 54 of 54 assets
Target & Modality
Belzutifan(Welireg)
Approved
HIF-2alphaSmall molecule
Renal Cell Carcinoma
Clesrovimab(Enflonsia)
Approved
RSV F proteinMonoclonal antibody
Respiratory Syncytial Virus Infection
Doravirine(Pifeltro)
Approved
HIV reverse transcriptaseSmall molecule
HIV
Approved
HIV reverse transcriptase · HIV-1 Reverse TranscriptaseSmall molecule
HIV
ensifentrine(Ohtuvayre)
Approved
PDE3/PDE4Small molecule
Chronic Obstructive Pulmonary Disease
Ertugliflozin(Steglatro)
Approved
SGLT2Small molecule
Type 2 Diabetes
Approved
Type I interferon receptorBiologic (subtype unspecified)
Chronic Hepatitis BFollicular LymphomaMelanoma
Approved
Glucocorticoid receptor; Beta-2 adrenergic receptorSmall molecule
Asthma
Approved
PARPSmall molecule
Breast CancerMetastatic Castration-Resistant Prostate CancerOvarian CancerPancreatic CancerProstate Cancer
HR+/HER2- Metastatic Breast Cancer
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung CancerBreast CancerOvarian CancerCervical CancerHepatocellular CarcinomaColorectal CancerMerkel Cell CarcinomaBiliary Tract CancerNon-Hodgkin LymphomaGastric CancerHead and Neck Squamous Cell CarcinomaSolid TumorsBladder / Urothelial CancerRenal Cell CarcinomaMelanomaEndometrial CancerEsophageal Cancer
HR+/HER2- Metastatic Breast Cancer, Large B-Cell Lymphoma, Urothelial Carcinoma, Metastatic Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Non-Muscle Invasive Bladder Cancer
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung CancerCervical CancerColorectal CancerBladder CancerGastric CancerSolid TumorsBreast CancerRenal Cell CarcinomaMelanoma
Raltegravir(Isentress)
Approved
HIV integraseSmall molecule
HIV
Riociguat(Adempas)
Approved
Soluble guanylate cyclaseSmall molecule
Pulmonary Arterial Hypertension
Sitagliptin(Januvia)
Approved
DPP-4Small molecule
Type 2 Diabetes
Sotatercept(Winrevair)
Approved
Activin receptor type IIA (ActRIIA)Protein / enzyme therapeutic
Heart FailurePulmonary Arterial Hypertension

Upcoming events

(189 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
November 2026 (1)
Sacituzumab TirumotecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2026-11 · NCT06448312 · CT.gov ↗
What to watch
December 2026 (4)
Sacituzumab TirumotecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2026-12 · NCT06711900 · CT.gov ↗
What to watch
Belzutifan · WeliregPhase 1/2Renal Cell Carcinoma
Est. primary completion 2026-12-22 · NCT05468697 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 2Selected Subjects With Advanced Solid Tumors
Est. primary completion 2026-12-30 · NCT05631262 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Metastatic Breast Cancer
Est. primary completion 2026-12-31 · NCT06081959 · CT.gov ↗
What to watch
2027 (54)
January 2027 (2)
PembrolizumabPhase 3Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-01-12 · NCT05609968 · CT.gov ↗
What to watch
PembrolizumabPhase 3Urinary Bladder Neoplasms
Est. primary completion 2027-01-31 · NCT04241185 · CT.gov ↗
What to watch
February 2027 (4)
HRS-5346Phase 2Lipoprotein Disorder
Est. primary completion 2027-02 · NCT07767513 · CT.gov ↗
What to watch
PembrolizumabPhase 2Hodgkin Lymphoma
Est. primary completion 2027-02-12 · NCT03407144 · CT.gov ↗
What to watch
tulisokibartPhase 2Psoriatic Arthritis
Est. primary completion 2027-02-17 · NCT07486960 · CT.gov ↗
What to watch
Belzutifan · WeliregPhase 2Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer, Renal Cell Carcinoma …
Est. primary completion 2027-02-26 · NCT03634540 · CT.gov ↗
What to watch
March 2027 (3)
ensifentrine · OhtuvayrePhase 2Pulmonary Disease, Chronic Obstructive, COPD
Est. primary completion 2027-03-01 · NCT05270525 · CT.gov ↗
What to watch
Pembrolizumab + Belzutifan · WeliregPhase 2Neoplasm Malignant
Est. primary completion 2027-03-22 · NCT04976634 · CT.gov ↗
What to watch
tulisokibartPhase 2Radiographic Axial Spondyloarthritis
Est. primary completion 2027-03-29 · NCT07133633 · CT.gov ↗
What to watch
April 2027 (5)
Sacituzumab TirumotecanPhase 3Triple Negative Breast Cancer
Est. primary completion 2027-04 · NCT06279364 · CT.gov ↗
What to watch
OlaparibPhase 3Ovarian Cancer, Breast Cancer
Est. primary completion 2027-04-06 · NCT04421963 · CT.gov ↗
What to watch
Intismeran AutogenePhase 1/2Bladder Cancer
Est. primary completion 2027-04-23 · NCT06305767 · CT.gov ↗
What to watch
Belzutifan · WeliregPhase 2VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation, VHL-Associated Renal Cell Carcinoma …
Est. primary completion 2027-04-29 · NCT03401788 · CT.gov ↗
What to watch
Ifinatamab DeruxtecanPhase 1/2Advanced Solid Tumor, Malignant Solid Tumor
Est. primary completion 2027-04-30 · NCT04145622 · CT.gov ↗
What to watch
May 2027 (9)
OlaparibPhase 2Metastatic Castration-resistant Prostate Cancer
Est. primary completion 2027-05 · NCT06909825 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2027-05 · NCT06670196 · CT.gov ↗
What to watch
PembrolizumabPhase 2Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor …
Est. primary completion 2027-05-04 · NCT02628067 · CT.gov ↗
What to watch
Belzutifan · WeliregPhase 2Metastatic Breast Cancer
Est. primary completion 2027-05-05 · NCT06428396 · CT.gov ↗
What to watch
Pembrolizumab + OlaparibPhase 3Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-05-05 · NCT04380636 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-05-10 · NCT06074588 · CT.gov ↗
What to watch
NemtabrutinibPhase 3Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Est. primary completion 2027-05-19 · NCT05624554 · CT.gov ↗
What to watch
PembrolizumabPhase 3Endometrial Neoplasms
Est. primary completion 2027-05-27 · NCT05173987 · CT.gov ↗
What to watch
PembrolizumabPhase 1/2Metastatic Urothelial Carcinoma, Urothelial Neoplasms
Est. primary completion 2027-05-31 · NCT05845814 · CT.gov ↗
What to watch
June 2027 (3)
Pembrolizumab + Sacituzumab TirumotecanPhase 1/2Esophageal Squamous Cell Carcinoma
Est. primary completion 2027-06-11 · NCT05319730 · CT.gov ↗
What to watch
Ifinatamab DeruxtecanPhase 1/2Oesophageal Squamous Cell Carcinoma
Est. primary completion 2027-06-12 · NCT07405151 · CT.gov ↗
What to watch
SKB571Phase 2Non-small Lung Cancer
Est. primary completion 2027-06-30 · NCT07308106 · CT.gov ↗
What to watch
July 2027 (8)
Sacituzumab TirumotecanPhase 3Metastatic Breast Cancer
Est. primary completion 2027-07 · NCT07071337 · CT.gov ↗
What to watch
MK-1406Phase 3Influenza
Est. primary completion 2027-07-02 · NCT07159763 · CT.gov ↗
What to watch
Pembrolizumab + Sacituzumab TirumotecanPhase 3Breast Neoplasms
Est. primary completion 2027-07-11 · NCT06312176 · CT.gov ↗
What to watch
BomedemstatPhase 3Essential Thrombocythemia
Est. primary completion 2027-07-14 · NCT06079879 · CT.gov ↗
What to watch
Ifinatamab DeruxtecanPhase 1/2Extensive Stage-small Cell Lung Cancer
Est. primary completion 2027-07-20 · NCT06362252 · CT.gov ↗
What to watch
AlimatravirPhase 3Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Est. primary completion 2027-07-22 · NCT07044297 · CT.gov ↗
What to watch
MK-3120Phase 1/2Bladder Cancer, Urinary Bladder Neoplasms
Est. primary completion 2027-07-30 · NCT07222488 · CT.gov ↗
What to watch
MK-1406Phase 2Healthy Participants
Est. primary completion 2027-07-31 · NCT07225959 · CT.gov ↗
What to watch
August 2027 (3)
Islatravir + UlonivirinePhase 2Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Est. primary completion 2027-08-10 · NCT06891066 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2027-08-31 · NCT07329322 · CT.gov ↗
What to watch
SKB571Phase 2Gastrointestinal Tumors
Est. primary completion 2027-08-31 · NCT07564466 · CT.gov ↗
What to watch
September 2027 (4)
NemtabrutinibPhase 1/2Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma …
Est. primary completion 2027-09-17 · NCT03162536 · CT.gov ↗
What to watch
ensifentrine · OhtuvayrePhase 2Non-cystic Fibrosis Bronchiectasis
Est. primary completion 2027-09-24 · NCT06559150 · CT.gov ↗
What to watch
Zilovertamab vedotinPhase 2/3DLBCL, Diffuse Large B-Cell Lymphoma
Est. primary completion 2027-09-24 · NCT05139017 · CT.gov ↗
What to watch
BomedemstatPhase 3Essential Thrombocythemia
Est. primary completion 2027-09-28 · NCT06456346 · CT.gov ↗
What to watch
October 2027 (6)
HRS-5346Phase 2Lipoprotein(a)
Est. primary completion 2027-10-12 · NCT07614984 · CT.gov ↗
What to watch
AlimatravirPhase 3Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Est. primary completion 2027-10-18 · NCT07071623 · CT.gov ↗
What to watch
MK-8690Phase 2Rheumatoid Arthritis
Est. primary completion 2027-10-19 · NCT07895524 · CT.gov ↗
What to watch
Pembrolizumab + Olaparib + Belzutifan · WeliregPhase 1/2Metastatic Castration-Resistant Prostate Cancer
Est. primary completion 2027-10-22 · NCT02861573 · CT.gov ↗
What to watch
MK-8690Phase 2Colitis Ulcerative, Ulcerative Colitis
Est. primary completion 2027-10-28 · NCT07463183 · CT.gov ↗
What to watch
Pembrolizumab + OlaparibPhase 3Small Cell Lung Cancer
Est. primary completion 2027-10-28 · NCT04624204 · CT.gov ↗
What to watch
November 2027 (3)
OpevesostatPhase 2Malignant Neoplasm
Est. primary completion 2027-11-04 · NCT06979596 · CT.gov ↗
What to watch
Enlicitide · LipfendraPhase 3Hyperlipidemia, Hypercholesterolemia
Est. primary completion 2027-11-26 · NCT07821944 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 2Solid Tumor
Est. primary completion 2027-11-30 · NCT05642780 · CT.gov ↗
What to watch
December 2027 (4)
AlimatravirPhase 2HIV
Est. primary completion 2027-12-02 · NCT07850609 · CT.gov ↗
What to watch
Zilovertamab vedotinPhase 2Lymphoma, Large B-Cell, Diffuse
Est. primary completion 2027-12-13 · NCT06890884 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 2Non-Squamous Non-Small Cell Lung Cancer
Est. primary completion 2027-12-30 · NCT07854509 · CT.gov ↗
What to watch
TucatinibPhase 3Colorectal Neoplasms
Est. primary completion 2027-12-31 · NCT05253651 · CT.gov ↗
What to watch
2028 (40)
January 2028 (8)
Sacituzumab TirumotecanPhase 2Ovarian Epithelial Cancer
Est. primary completion 2028-01 · NCT07341100 · CT.gov ↗
What to watch
Intismeran AutogenePhase 2Renal Cell Carcinoma
Est. primary completion 2028-01-08 · NCT06307431 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Endometrial Cancer
Est. primary completion 2028-01-10 · NCT06132958 · CT.gov ↗
What to watch
SKB571Phase 2Lung Cancer (Non-Small Cell)
Est. primary completion 2028-01-19 · NCT07230405 · CT.gov ↗
What to watch
CalderasibPhase 3Non-small Cell Lung Cancer
Est. primary completion 2028-01-24 · NCT06345729 · CT.gov ↗
What to watch
Pembrolizumab + Sacituzumab TirumotecanPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2028-01-25 · NCT06170788 · CT.gov ↗
What to watch
Ifinatamab Deruxtecan + GocatamigPhase 1/2Small-Cell Lung Cancer, Neuroendocrine Carcinoma
Est. primary completion 2028-01-28 · NCT04471727 · CT.gov ↗
What to watch
Ifinatamab DeruxtecanPhase 3Small Cell Lung Cancer
Est. primary completion 2028-01-30 · NCT06203210 · CT.gov ↗
What to watch
February 2028 (4)
PembrolizumabPhase 1/2Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
Est. primary completion 2028-02-02 · NCT02332668 · CT.gov ↗
What to watch
MK-3120Phase 1/2Advanced Solid Tumors, Malignant Neoplasm
Est. primary completion 2028-02-08 · NCT06818643 · CT.gov ↗
What to watch
SKB571Phase 2Pancreatic Cancer
Est. primary completion 2028-02-28 · NCT07814066 · CT.gov ↗
What to watch
Raludotatug DeruxtecanPhase 2/3Solid Cancer
Est. primary completion 2028-02-29 · NCT06161025 · CT.gov ↗
What to watch
March 2028 (2)
Pembrolizumab + Sacituzumab TirumotecanPhase 1/2Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Est. primary completion 2028-03-31 · NCT06483334 · CT.gov ↗
What to watch
Est. primary completion 2028-03-31 · NCT06041802 · CT.gov ↗
What to watch
April 2028 (1)
Sacituzumab TirumotecanPhase 2Thymic Carcinoma
Est. primary completion 2028-04 · NCT07324629 · CT.gov ↗
What to watch
May 2028 (2)
Patritumab Deruxtecan + Sacituzumab TirumotecanPhase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Est. primary completion 2028-05-09 · NCT06445972 · CT.gov ↗
What to watch
OpevesostatPhase 3Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Est. primary completion 2028-05-10 · NCT06136650 · CT.gov ↗
What to watch
June 2028 (4)
Ifinatamab DeruxtecanPhase 3Esophageal Squamous Cell Carcinoma
Est. primary completion 2028-06-01 · NCT06644781 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Cervical Cancer
Est. primary completion 2028-06-15 · NCT06459180 · CT.gov ↗
What to watch
Sotatercept · WinrevairPhase 2Pulmonary Arterial Hypertension
Est. primary completion 2028-06-16 · NCT06925750 · CT.gov ↗
What to watch
Ifinatamab DeruxtecanPhase 3Prostate Cancer, Prostatic Neoplasms
Est. primary completion 2028-06-26 · NCT06925737 · CT.gov ↗
What to watch
July 2028 (3)
Intismeran AutogenePhase 2Malignant Melanoma
Est. primary completion 2028-07-22 · NCT06961006 · CT.gov ↗
What to watch
Ifinatamab DeruxtecanPhase 1/2Recurrent or Metastatic Solid Tumors
Est. primary completion 2028-07-25 · NCT06330064 · CT.gov ↗
What to watch
PembrolizumabPhase 3High-risk Non-muscle Invasive Bladder Cancer
Est. primary completion 2028-07-31 · NCT03711032 · CT.gov ↗
What to watch
August 2028 (2)
Est. primary completion 2028-08 · NCT07697586 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2028-08-17 · NCT06305754 · CT.gov ↗
What to watch
September 2028 (4)
PembrolizumabPhase 3Colorectal Neoplasms
Est. primary completion 2028-09-19 · NCT05239741 · CT.gov ↗
What to watch
Sotatercept · WinrevairPhase 2Pulmonary Arterial Hypertension
Est. primary completion 2028-09-21 · NCT05587712 · CT.gov ↗
What to watch
Belzutifan · WeliregPhase 2Malignant Neoplam, Advanced Solid Tumors
Est. primary completion 2028-09-26 · NCT07793942 · CT.gov ↗
What to watch
SKB571Phase 2HNSCC
Est. primary completion 2028-09-30 · NCT07668154 · CT.gov ↗
What to watch
October 2028 (2)
Enlicitide · LipfendraPhase 3Hypercholesterolemia
Est. primary completion 2028-10-13 · NCT06492291 · CT.gov ↗
What to watch
tulisokibartPhase 3Crohn's Disease
Est. primary completion 2028-10-30 · NCT06430801 · CT.gov ↗
What to watch
November 2028 (5)
Pembrolizumab berahyaluronidase alfa · Keytruda QlexPhase 2Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent …
Est. primary completion 2028-11-08 · NCT06504394 · CT.gov ↗
What to watch
Doravirine · PifeltroPhase 2Human Immunodeficiency Virus (HIV) Infection
Est. primary completion 2028-11-12 · NCT04375800 · CT.gov ↗
What to watch
OlaparibPhase 3Breast Cancer
Est. primary completion 2028-11-20 · NCT06112379 · CT.gov ↗
What to watch
OlaparibPhase 3Advanced or Recurrent Endometrial Cancer
Est. primary completion 2028-11-30 · NCT06746116 · CT.gov ↗
What to watch
OpevesostatPhase 3Prostate Cancer Metastatic
Est. primary completion 2028-11-30 · NCT06136624 · CT.gov ↗
What to watch
December 2028 (3)
Patritumab DeruxtecanPhase 1/2Gastrointestinal Cancer
Est. primary completion 2028-12-07 · NCT06596694 · CT.gov ↗
What to watch
Sotatercept · WinrevairPhase 3Pulmonary Arterial Hypertension
Est. primary completion 2028-12-07 · NCT07218029 · CT.gov ↗
What to watch
SKB571Phase 2Non-Small Cell Lung Cancer
Est. primary completion 2028-12-31 · NCT07622186 · CT.gov ↗
What to watch
2029 (37)
January 2029 (3)
NemtabrutinibPhase 2Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Est. primary completion 2029-01-04 · NCT04728893 · CT.gov ↗
What to watch
Pembrolizumab + Sacituzumab TirumotecanPhase 3Non-small Cell Lung Cancer, NSCLC
Est. primary completion 2029-01-12 · NCT06422143 · CT.gov ↗
What to watch
Olaparib + OpevesostatPhase 1/2Prostatic Neoplasms, Castration-Resistant
Est. primary completion 2029-01-15 · NCT06353386 · CT.gov ↗
What to watch
February 2029 (3)
Islatravir + UlonivirinePhase 2/3Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Est. primary completion 2029-02-01 · NCT07266831 · CT.gov ↗
What to watch
Ifinatamab Deruxtecan + GocatamigPhase 1/2Small Cell Lung Cancer
Est. primary completion 2029-02-15 · NCT06780137 · CT.gov ↗
What to watch
Pembrolizumab + Zilovertamab vedotin + MK-3120Phase 1/2Urothelial Carcinoma
Est. primary completion 2029-02-26 · NCT05562830 · CT.gov ↗
What to watch
March 2029 (4)
Pembrolizumab + Raludotatug DeruxtecanPhase 1/2Ovarian Cancer Recurrent
Est. primary completion 2029-03-27 · NCT06843447 · CT.gov ↗
What to watch
CalderasibPhase 3Colon Adenocarcinoma, Rectal Adenocarcinoma
Est. primary completion 2029-03-28 · NCT06997497 · CT.gov ↗
What to watch
PembrolizumabPhase 1/2Malignant Neoplasm, Carcinoma, Merkel Cell, Lymphoma
Est. primary completion 2029-03-30 · NCT07302347 · CT.gov ↗
What to watch
Zilovertamab vedotinPhase 1/2B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
Est. primary completion 2029-03-31 · NCT06395103 · CT.gov ↗
What to watch
April 2029 (5)
SKB571Phase 1/2Advanced Solid Tumors, Malignant Neoplasm
Est. primary completion 2029-04-12 · NCT07876128 · CT.gov ↗
What to watch
Zilovertamab vedotinPhase 2Lymphoma, Large B-Cell, Diffuse (DLBCL)
Est. primary completion 2029-04-26 · NCT05406401 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Est. primary completion 2029-04-27 · NCT06824467 · CT.gov ↗
What to watch
ensifentrine · OhtuvayrePhase 3Pulmonary Disease, Chronic Obstructive
Est. primary completion 2029-04-29 · NCT07874815 · CT.gov ↗
What to watch
MK-2214Phase 2Early Alzheimer's Disease
Est. primary completion 2029-04-30 · NCT07033494 · CT.gov ↗
What to watch
May 2029 (3)
Zilovertamab vedotin + NemtabrutinibPhase 2Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Est. primary completion 2029-05-17 · NCT05458297 · CT.gov ↗
What to watch
Sotatercept · WinrevairPhase 2Pulmonary Arterial Hypertension
Est. primary completion 2029-05-24 · NCT07646860 · CT.gov ↗
What to watch
Doravirine/islatravir (Idvynso)Phase 3HIV-1 Infection
Est. primary completion 2029-05-29 · NCT04776252 · CT.gov ↗
What to watch
June 2029 (1)
tulisokibartPhase 2Noninfectious Intermediate, Posterior, or Panuveitis
Est. primary completion 2029-06-05 · NCT07861074 · CT.gov ↗
What to watch
July 2029 (5)
Raludotatug DeruxtecanPhase 3Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
Est. primary completion 2029-07-01 · NCT07791732 · CT.gov ↗
What to watch
Pembrolizumab + Intismeran AutogenePhase 2Squamous Non-small Cell Lung Cancer
Est. primary completion 2029-07-02 · NCT07221474 · CT.gov ↗
What to watch
Zilovertamab vedotinPhase 3Diffuse Large B-Cell Lymphoma
Est. primary completion 2029-07-02 · NCT06717347 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 3Bladder Cancer
Est. primary completion 2029-07-27 · NCT07419295 · CT.gov ↗
What to watch
TucatinibPhase 2Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms …
Est. primary completion 2029-07-28 · NCT06157892 · CT.gov ↗
What to watch
August 2029 (2)
Patritumab Deruxtecan + Calderasib + Sacituzumab TirumotecanPhase 1/2Lung Neoplasm Malignant
Est. primary completion 2029-08-17 · NCT07286149 · CT.gov ↗
What to watch
Vericiguat · VerquvoPhase 2/3Heart Failure, Left Ventricular Systolic Dysfunction
Est. primary completion 2029-08-20 · NCT05714085 · CT.gov ↗
What to watch
September 2029 (1)
Pembrolizumab + Patritumab Deruxtecan + Sacituzumab TirumotecanPhase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Est. primary completion 2029-09-12 · NCT06469944 · CT.gov ↗
What to watch
October 2029 (3)
tulisokibartPhase 2Pulmonary Sarcoidosis
Est. primary completion 2029-10-05 · NCT07867938 · CT.gov ↗
What to watch
Pembrolizumab + Sacituzumab TirumotecanPhase 1/2Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Est. primary completion 2029-10-16 · NCT06428409 · CT.gov ↗
What to watch
Intismeran AutogenePhase 3Melanoma
Est. primary completion 2029-10-26 · NCT05933577 · CT.gov ↗
What to watch
November 2029 (2)
Pembrolizumab + Calderasib + Sacituzumab TirumotecanPhase 2Malignant Neoplasm
Est. primary completion 2029-11-15 · NCT07252739 · CT.gov ↗
What to watch
Enlicitide · LipfendraPhase 3Arteriosclerosis, Hypercholesterolaemia
Est. primary completion 2029-11-29 · NCT06008756 · CT.gov ↗
What to watch
December 2029 (5)
Sacituzumab TirumotecanPhase 1/2Advanced Solid Tumors
Est. primary completion 2029-12 · NCT07586943 · CT.gov ↗
What to watch
Est. primary completion 2029-12-07 · NCT07190248 · CT.gov ↗
What to watch
Pembrolizumab + Raludotatug DeruxtecanPhase 1/2Small Cell Lung Carcinoma
Est. primary completion 2029-12-10 · NCT04938817 · CT.gov ↗
What to watch
Raludotatug DeruxtecanPhase 2Advanced Solid Tumor, Metastatic Solid Tumors
Est. primary completion 2029-12-30 · NCT06660654 · CT.gov ↗
What to watch
Pembrolizumab + Patritumab Deruxtecan + OlaparibPhase 2Breast Neoplasms, Breast Cancer
Est. primary completion 2029-12-31 · NCT06797635 · CT.gov ↗
What to watch
2030 (7)
January 2030 (1)
Sotatercept · WinrevairPhase 3Pulmonary Hypertension
Est. primary completion 2030-01-08 · NCT07839585 · CT.gov ↗
What to watch
May 2030 (1)
Pembrolizumab + Sacituzumab TirumotecanPhase 3Triple Negative Breast Neoplasms
Est. primary completion 2030-05-18 · NCT06841354 · CT.gov ↗
What to watch
June 2030 (1)
Intismeran AutogenePhase 3Non-small Cell Lung Cancer
Est. primary completion 2030-06-25 · NCT06077760 · CT.gov ↗
What to watch
November 2030 (2)
Patritumab DeruxtecanPhase 2Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer …
Est. primary completion 2030-11-19 · NCT06172478 · CT.gov ↗
What to watch
Ifinatamab Deruxtecan + GocatamigPhase 1/2Small Cell Lung Cancer Extensive Stage
Est. primary completion 2030-11-29 · NCT07227597 · CT.gov ↗
What to watch
December 2030 (2)
Pembrolizumab + Sacituzumab TirumotecanPhase 3Triple-Negative Breast Cancer
Est. primary completion 2030-12-16 · NCT06393374 · CT.gov ↗
What to watch
Patritumab DeruxtecanPhase 1/2Malignant Neoplasm
Est. primary completion 2030-12-30 · NCT06941272 · CT.gov ↗
What to watch
2031 (13)
January 2031 (2)
Patritumab DeruxtecanPhase 1/2Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
Est. primary completion 2031-01-01 · NCT07701941 · CT.gov ↗
What to watch
PembrolizumabPhase 3Breast Cancer
Est. primary completion 2031-01-24 · NCT03725059 · CT.gov ↗
What to watch
July 2031 (1)
Pembrolizumab + MK-3120Phase 1/2Bladder Cancer
Est. primary completion 2031-07-08 · NCT07232602 · CT.gov ↗
What to watch
August 2031 (2)
Ifinatamab DeruxtecanPhase 1/2Malignant Neoplasm
Est. primary completion 2031-08-17 · NCT07630974 · CT.gov ↗
What to watch
Raludotatug DeruxtecanPhase 3Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Est. primary completion 2031-08-31 · NCT07743164 · CT.gov ↗
What to watch
September 2031 (3)
Intismeran AutogenePhase 2Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Est. primary completion 2031-09-03 · NCT06833073 · CT.gov ↗
What to watch
V181Phase 3Healthy
Est. primary completion 2031-09-06 · NCT07013487 · CT.gov ↗
What to watch
Sacituzumab TirumotecanPhase 2Advanced Solid Tumors, Malignant Neoplasm
Est. primary completion 2031-09-30 · NCT07785609 · CT.gov ↗
What to watch
October 2031 (3)
Ifinatamab Deruxtecan + OpevesostatPhase 1/2Castration-Resistant Prostatic Cancer, Metastasis
Est. primary completion 2031-10-01 · NCT06863272 · CT.gov ↗
What to watch
Belzutifan · WeliregPhase 1/2Renal Cell Carcinoma
Est. primary completion 2031-10-26 · NCT07049926 · CT.gov ↗
What to watch
Pembrolizumab + Sacituzumab TirumotecanPhase 3Cervical Cancer
Est. primary completion 2031-10-29 · NCT07216703 · CT.gov ↗
What to watch
November 2031 (1)
Est. primary completion 2031-11-17 · NCT07829783 · CT.gov ↗
What to watch
December 2031 (1)
GocatamigPhase 3Small Cell Lung Cancer
Est. primary completion 2031-12-08 · NCT07908537 · CT.gov ↗
What to watch
2032 (18)
January 2032 (1)
Pembrolizumab + Sacituzumab Tirumotecan + Ifinatamab DeruxtecanPhase 1/2Esophageal Squamous Cell Carcinoma
Est. primary completion 2032-01-04 · NCT06780111 · CT.gov ↗
What to watch
February 2032 (3)
Pembrolizumab + Sacituzumab TirumotecanPhase 2Lung Neoplasm Malignant
Est. primary completion 2032-02-06 · NCT06788912 · CT.gov ↗
What to watch
Pembrolizumab + Patritumab Deruxtecan + Boserolimab + Ifinatamab DeruxtecanPhase 1/2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2032-02-13 · NCT04165070 · CT.gov ↗
What to watch
Belzutifan · WeliregPhase 3Renal Cell Carcinoma
Est. primary completion 2032-02-27 · NCT07227402 · CT.gov ↗
What to watch
March 2032 (4)
Est. primary completion 2032-03-02 · NCT06780098 · CT.gov ↗
What to watch
Ifinatamab Deruxtecan + Raludotatug DeruxtecanPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2032-03-12 · NCT06780085 · CT.gov ↗
What to watch
Pembrolizumab + Patritumab DeruxtecanPhase 2Non-small Cell Lung Cancer
Est. primary completion 2032-03-12 · NCT06731907 · CT.gov ↗
What to watch
Raludotatug DeruxtecanPhase 3Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
Est. primary completion 2032-03-19 · NCT07776691 · CT.gov ↗
What to watch
April 2032 (1)
CalderasibPhase 2Neoplasm Malignant
Est. primary completion 2032-04-09 · NCT07209111 · CT.gov ↗
What to watch
May 2032 (1)
Pembrolizumab + Sacituzumab TirumotecanPhase 3Endometrial Cancer
Est. primary completion 2032-05-24 · NCT06952504 · CT.gov ↗
What to watch
June 2032 (3)
NemtabrutinibPhase 3Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
Est. primary completion 2032-06-01 · NCT05947851 · CT.gov ↗
What to watch
BomedemstatPhase 2/3Polycythemia Vera
Est. primary completion 2032-06-25 · NCT07722611 · CT.gov ↗
What to watch
Sacituzumab Tirumotecan + OpevesostatPhase 1/2Metastatic Castration-resistant Prostate Cancer
Est. primary completion 2032-06-29 · NCT07908524 · CT.gov ↗
What to watch
August 2032 (1)
Patritumab Deruxtecan + TucatinibPhase 1/2Breast Neoplasms, Breast Cancer
Est. primary completion 2032-08-02 · NCT06686394 · CT.gov ↗
What to watch
September 2032 (1)
NemtabrutinibPhase 3Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Est. primary completion 2032-09-07 · NCT06136559 · CT.gov ↗
What to watch
November 2032 (2)
Belzutifan · WeliregPhase 2Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor …
Est. primary completion 2032-11-18 · NCT04924075 · CT.gov ↗
What to watch
Intismeran AutogenePhase 2Melanoma
Est. primary completion 2032-11-21 · NCT03897881 · CT.gov ↗
What to watch
December 2032 (1)
CalderasibPhase 3Non-small Cell Lung Cancer
Est. primary completion 2032-12-15 · NCT07554339 · CT.gov ↗
What to watch
2033 (5)
February 2033 (1)
Sacituzumab TirumotecanPhase 3Ovarian Neoplasms, Ovarian Cancer
Est. primary completion 2033-02-25 · NCT07318558 · CT.gov ↗
What to watch
March 2033 (1)
Sacituzumab Tirumotecan + OlaparibPhase 3Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Est. primary completion 2033-03-23 · NCT06966700 · CT.gov ↗
What to watch
May 2033 (1)
Intismeran AutogenePhase 3Carcinoma, Non-Small-Cell Lung
Est. primary completion 2033-05-16 · NCT06623422 · CT.gov ↗
What to watch
July 2033 (1)
Patritumab DeruxtecanPhase 3Breast Neoplasms
Est. primary completion 2033-07-14 · NCT07060807 · CT.gov ↗
What to watch
December 2033 (1)
Enlicitide · LipfendraPhase 2/3Heterozygous Familial Hypercholesterolemia (HeFH)
Est. primary completion 2033-12-04 · NCT07058077 · CT.gov ↗
What to watch
2034 (5)
January 2034 (1)
Belzutifan · WeliregPhase 2Malignant Neoplasm
Est. primary completion 2034-01-02 · NCT07700758 · CT.gov ↗
What to watch
February 2034 (1)
Pembrolizumab + Sacituzumab TirumotecanPhase 3Non Small Cell Lung Cancer
Est. primary completion 2034-02-21 · NCT06312137 · CT.gov ↗
What to watch
April 2034 (1)
Belzutifan · WeliregPhase 3Von Hippel-Lindau Disease, Malignant Neoplasms
Est. primary completion 2034-04-22 · NCT07405164 · CT.gov ↗
What to watch
August 2034 (1)
Est. primary completion 2034-08-22 · NCT07513376 · CT.gov ↗
What to watch
December 2034 (1)
BomedemstatPhase 3Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis …
Est. primary completion 2034-12-04 · NCT06351631 · CT.gov ↗
What to watch
2035 (1)
August 2035 (1)
Sotatercept · WinrevairPhase 2Hypertension, Pulmonary
Est. primary completion 2035-08-10 · NCT06814145 · CT.gov ↗
What to watch
2037 (2)
March 2037 (1)
Zilovertamab vedotinPhase 2/3Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma
Est. primary completion 2037-03-13 · NCT07917754 · CT.gov ↗
What to watch
December 2037 (1)
tulisokibartPhase 3Crohn Disease, Colitis, Ulcerative
Est. primary completion 2037-12-17 · NCT06651281 · CT.gov ↗
What to watch
2039 (1)
October 2039 (1)
CalderasibPhase 3Non-small Cell Lung Cancer
Est. primary completion 2039-10-26 · NCT07431827 · CT.gov ↗
What to watch
2043 (1)
August 2043 (1)
Pembrolizumab + Olaparib + Pembrolizumab berahyaluronidase alfa · Keytruda QlexPhase 3Solid Tumors, Hematologic Malignancies
Est. primary completion 2043-08-04 · NCT03486873 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(27)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

21 October 2026ApprovalPembrolizumabEC approves KEYTRUDA plus Padcev perioperatively in resectable MIBC
EU, EC · Source ↗
7 October 2026ApprovalTucatinibFDA approves TUKYSA with trastuzumab and pertuzumab as first-line maintenance in HER2-positive metastatic breast cancer (HER2CLIMB-05)
US, FDA · Source ↗
4 October 2026FDA action dateLenvatinibFDA PDUFA date for LENVIMA plus WELIREG in RCC
US, FDA · Source ↗
October 2026ApprovalTucatinibFDA updates Boxed Warning on Tucatinib (NDA213411)
US, FDA · FDA · Source ↗
25 September 2026WithdrawalIfinatamab DeruxtecanUS BLA for ifinatamab deruxtecan in pretreated ES-SCLC voluntarily withdrawn
US, FDA · Daiichi Sankyo · Source ↗
31 August 2026Topline resultHRS-5346Phase 2 study of oral HRS-5346 (NCT06816264) in adults at high cardiovascular risk with elevated Lp(a) presented at ESC 2026: HRS-5346 reduced Lp(a)
Jiangsu Hengrui Pharmaceuticals · Source ↗
19 August 2026Topline resultIntismeran AutogeneINTerpath-001 Phase 3 of intismeran autogene plus pembrolizumab meets RFS primary endpoint in resected melanoma
Merck & Co. and Moderna · Source ↗
17 August 2026FDA action datePembrolizumabPDUFA target action date set
US, FDA · Source ↗
August 2026ApprovalRiociguatFDA updates Boxed Warning on Adempas (NDA204819)
US, FDA · FDA · Source ↗
30 July 2026Filing acceptedSacituzumab tirumotecan (sac-TMT)NMPA accepts the new indication application for sac-TMT in first-line advanced TNBC
China, NMPA · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Source ↗
8 June 2026Topline resultIslatravir/lenacapavirPhase 3 ISLEND-1 and ISLEND-2 of once-weekly oral islatravir/lenacapavir met their Week 48 primary endpoint
Gilead Sciences and Merck · Source ↗
8 June 2026Topline resultIslatravir/lenacapavirGilead and Merck: Phase 3 ISLEND-1 and ISLEND-2 of once-weekly oral islatravir/lenacapavir met their Week 48 primary endpoint
Gilead Sciences and Merck · Source ↗

The 12 most recent of 27 past events are shown.

Financial reports

Quarterly & interim (18)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$18.1B$4.5B$9.7B+ $100M short-term inv.—$6.6B operating cash flowreport ↗
View 17 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$16.6B$9.7B$6.9B+ $292M short-term inv.$1.3B$5.4B operating cash flowreport ↗
2026-Q1$16.3B$12.6B$5.4B+ $375M short-term inv.$4.2B$3.9B operating cash flowreport ↗
2025-Q4$16.4B$3.9B$14.6B—report ↗
2025-Q3$17.3B$4.2B$18.2B+ $45M short-term inv.—$7.8B operating cash flowreport ↗
2025-Q2$15.8B$4.0B$8.6B+ $615M short-term inv.—$3.3B operating cash flowreport ↗
2025-Q1$15.5B$3.6B$9.2B+ $599M short-term inv.—$2.5B operating cash flowreport ↗
2024-Q4$15.6B$4.6B$13.7B—report ↗
2024-Q3$16.7B$5.9B$14.6B+ $0 short-term inv.—$9.3B operating cash flowreport ↗
2024-Q2$16.1B$3.5B$11.4B+ $50M short-term inv.—$5.6B operating cash flowreport ↗
2024-Q1$15.8B$4.0B$5.7B+ $40M short-term inv.—$3.1B operating cash flowreport ↗
2023-Q3$16.0B$3.3B$8.7B+ $168M short-term inv.—$7.7B operating cash flowreport ↗
2023-Q2$15.0B$13.3B$5.7B+ $718M short-term inv.$6.0B$3.7B operating cash flowreport ↗
2023-Q1$14.5B$4.3B$9.8B+ $680M short-term inv.—$1.3B operating cash flowreport ↗
2022-Q3$15.0B$4.4B$11.3B+ $103M short-term inv.—$5.6B operating cash flowreport ↗
2022-Q2$14.6B$2.8B$9.8B+ $453M short-term inv.—$4.3B operating cash flowreport ↗
2022-Q1$15.9B$2.6B$8.6B+ $372M short-term inv.—$4.8B operating cash flowreport ↗
2021-Q3$13.2B$2.4B$10.0B—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$65.0B$15.8B$14.6B+ $0 short-term inv.—$16.5B operating cash flowreport ↗

Merck reported full-year 2025 revenue of $65,011M, up 1% YoY, with R&D spend of $15,789M, down 12% YoY, and cash and equivalents of $14,565M. GAAP net income was $18,254M, with GAAP EPS of $7.28 and non-GAAP EPS of $8.98.

The company guided full-year 2026 sales to $65.5B–$67.0B and non-GAAP EPS to $5.00–$5.15, including a one-time charge of approximately $3.65 per share related to the Cidara acquisition. It highlighted positive results from 18 Phase 3 trials in 2025, including enlicitide, doravirine/islatravir, and KEYTRUDA-based regimens; advanced WINREVAIR and sac-TMT regulatory milestones; and expanded its pipeline through acquisitions of Verona Pharma and Cidara Therapeutics, a license agreement with Hengrui Pharma, and a U.S. government agreement to broaden medicine access and lower costs.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$64.2B$17.9B$13.7B+ $447M short-term inv.—$21.5B operating cash flowreport ↗
2023-FY$60.1B$30.5B$7.1B+ $252M short-term inv.—$13.0B operating cash flowreport ↗
2022-FY$59.3B$13.5B$12.8B+ $498M short-term inv.—$19.1B operating cash flowreport ↗
2021-FY$48.7B$12.2B$8.2B+ $0 short-term inv.—report ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 34 sales ($79.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-12DeLuca Richard R. · EVP&Pres, Merck Animal HeallthOption exercise58,185$77.62$4.5MForm 4
2026-11-12DeLuca Richard R. · EVP&Pres, Merck Animal HeallthOpen-market sale58,185$148.01$8.6MForm 4
2026-11-12DeLuca Richard R. · EVP&Pres, Merck Animal HeallthOption exercise (derivative)58,185——Form 4
2026-11-01DIAZ PAUL J · directorAward / grant (derivative)613.073$149.52$92KForm 4
2026-09-30Coe Mary Ellen · directorAward / grant (derivative)206.455$145.31$30KForm 4
2026-09-30Karsanbhai Surendralal Lanca · directorAward / grant (derivative)111.83$145.31$16KForm 4
2026-09-30Seidman Christine E · directorAward / grant (derivative)55.915$145.31$8KForm 4
2026-08-13Guindo Chirfi · EVP, Access, Policy & CommsOpen-market sale10,000$135.00$1.4MForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 3,694 reporting institutions held 1924.2M shares ($221.8B, 78.1% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.225,830,330$27.2B
2VANGUARD CAPITAL MANAGEMENT LLC160,987,624$19.4B
3STATE STREET CORP119,325,673$14.5B
4WELLINGTON MANAGEMENT GROUP LLP84,314,971$10.1B
5VANGUARD PORTFOLIO MANAGEMENT LLC67,304,305$8.1B
6GEODE CAPITAL MANAGEMENT, LLC59,558,154$7.1B
7JPMORGAN CHASE & CO52,972,983$6.3B
8CHARLES SCHWAB INVESTMENT MANAGEMENT INC49,765,225$6.0B
9MORGAN STANLEY47,632,487$5.7B
10FMR LLC44,516,010$5.4B
11BANK OF AMERICA CORP /DE/30,774,221$3.7B
12NORTHERN TRUST CORP27,090,023$3.3B
13Fisher Asset Management, LLC26,436,284$3.2B
14Invesco Ltd.21,855,101$2.6B
15UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC20,414,819$2.5B